{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:46:19Z","timestamp":1770813979222,"version":"3.50.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Localized Scleroderma (LoS), particularly aggressive subtypes such as Deep Morphea (morphea profunda), is a rare chronic autoimmune fibrosing disorder that can extend into the subcutaneous tissue, fascia, and muscle. These deep forms carry a high risk of functional impairment. Tocilizumab (TCZ), an anti-interleukin-6 (IL-6) receptor antibody, has emerged as a promising therapy for severe, refractory cases. However, its reported use typically follows the failure of standard immunosuppressive agents like methotrexate (MTX).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report the case of a 19-year-old male with a rapidly progressive deep morphea of the left lower extremity, with only a two-month history from onset. Initial symptoms included skin hardening, hyperpigmentation, and mild restriction of foot motion. Skin biopsy confirmed deep morphea, showing lymphoplasmacytic inflammation and eosinophilic fibrosis extending into the subcutaneous septa and muscle interstitium. Pre-treatment magnetic resonance imaging (MRI) revealed prominent edema (high T2 signal) in the subcutaneous fat and blurred muscle fascial planes, consistent with active deep inflammation. Uniquely, the patient was seropositive for multiple antiphospholipid antibodies (aPLs), including Lupus Anticoagulant (dRVVT ratio 1.34), anti-phosphatidylserine\/prothrombin IgM (143.72 U), \u03b22-glycoprotein I IgM (30.9 CU), and anticardiolipin IgM (28.2 CU). Given the rapid progression and deep tissue involvement, an early intensified combination regimen of TCZ (640 mg IV every 4 weeks), MTX (12.5 mg weekly), high-dose corticosteroids (IV pulses followed by 30 mg\/day oral prednisone taper), and prophylactic aspirin (100 mg daily) was initiated. Follow-up MRI at six months showed a marked reduction in the deep tissue edema, correlating with significant clinical improvement in skin induration and tightening by nine months post-treatment. No serious adverse events were observed during follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case demonstrates the successful outcome of early TCZ-based combination therapy in rapidly controlling the aggressive inflammatory process of an adult deep morphea. The objective radiological response validates this early intervention strategy, which deviates from the typical second-line use of TCZ. Furthermore, the case highlights a rare but clinically important overlap between severe localized scleroderma and multiple aPL seropositivity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1764835","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T07:37:04Z","timestamp":1770795424000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Successful tocilizumab-based combination therapy for a case of rapidly progressive adult deep morphea with multiple antiphospholipid antibodies: a case report and literature review"],"prefix":"10.3389","volume":"17","author":[{"given":"Ruohan","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Guang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yadan","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanjun","family":"Yue","sequence":"additional","affiliation":[{"name":"Department of Pathology, Peking University International Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1590\/abd1806-4841.20152890","article-title":"Localized scleroderma: clinical spectrum and therapeutic update","volume":"90","author":"Careta","year":"2015","journal-title":"Bras Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/01.bor.0000245727.40630.c3","article-title":"Localized scleroderma","volume":"18","author":"Laxer","year":"2006","journal-title":"Curr Opin Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei251","article-title":"Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study","volume":"45","author":"Zulian","year":"2006","journal-title":"Rheumatol (Oxford)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1136\/annrheumdis-2018-214697","article-title":"Consensus-based recommendations for the management of juvenile localised scleroderma","volume":"78","author":"Zulian","year":"2019","journal-title":"Ann Rheumatic Diseases"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1002\/art.30264","article-title":"Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial","volume":"63","author":"Zulian","year":"2011","journal-title":"Arthritis Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14458","article-title":"European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes","volume":"31","author":"Knobler","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15328","article-title":"S2k guideline: Diagnosis and therapy of localized scleroderma","volume":"22","author":"Kreuter","year":"2024","journal-title":"J Dtsch Dermatol Ges"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21687","article-title":"Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma","volume":"64","author":"Li","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.09.024","article-title":"Tocilizumab for refractory morphea in adults: A case series","volume":"30","author":"Lonowski","year":"2022","journal-title":"JAAD Case Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19692","article-title":"Tocilizumab for refractory post-COVID-19 pansclerotic morphea","volume":"38","author":"Saraswat","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/rheumatology\/kex382","article-title":"Tocilizumab as a potential therapeutic option for children with severe, refractory juvenile localized scleroderma","volume":"57","author":"Lythgoe","year":"2018","journal-title":"Rheumatol (United Kingdom)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.02.004","article-title":"Disease course and long-term outcome of juvenile localized scleroderma: Experience from a single pediatric rheumatology Centre and literature review","volume":"17","author":"Martini","year":"2018","journal-title":"Autoimmun Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.sder.2007.02.005","article-title":"Deep morphea","volume":"26","author":"Bielsa","year":"2007","journal-title":"Semin Cutan Med Surg"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.11102136","article-title":"Localized scleroderma: MR findings and clinical features","volume":"260","author":"Schanz","year":"2011","journal-title":"Radiology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13790","article-title":"A systematic review of tools for determining activity of localized scleroderma in paediatric and adult patients","volume":"31","author":"Lis-Swiety","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.5334\/jbsr.2805","article-title":"MRI findings of eosinophilic fasciitis","volume":"106","author":"Kubincov\u00e1","year":"2022","journal-title":"J Belg Soc Radiol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1177\/12034754241291045","article-title":"Tocilizumab for the treatment of refractory morphea: A systematic review","volume":"29","author":"Metko","year":"2025","journal-title":"J Cutaneous Med Surgery"},{"key":"B18","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3390\/ph18050643","article-title":"New challenging systemic therapies for juvenile scleroderma: A comprehensive review","volume":"18","author":"Sassetti","year":"2025","journal-title":"Pharmaceuticals"},{"key":"B19","doi-asserted-by":"publisher","first-page":"152634","DOI":"10.1016\/j.semarthrit.2025.152634","article-title":"Use of biologic drug in the treatment of localized scleroderma and systemic sclerosis in children: A scoping review","volume":"71","author":"Sener","year":"2025","journal-title":"Semin Arthritis Rheumatism"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.5301\/jsrd.5000259","article-title":"Tocilizumab is a promising treatment option for therapy resistant juvenile localized scleroderma patients","volume":"2","author":"Foeldvari","year":"2017","journal-title":"J Scleroderma Related Disord"},{"key":"B21","article-title":"Tocilizumab in two children with pansclerotic morphoea: A hopeful therapy for refractory cases","volume":"35","author":"Martini","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.5040","article-title":"A case of pansclerotic morphea treated with tocilizumab","volume":"155","author":"Zhang","year":"2019","journal-title":"JAMA Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.656407","article-title":"Case report: pansclerotic morphea-clinical features, differential diagnoses and modern treatment concepts","volume":"12","author":"Vent\u00e9jou","year":"2021","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13023-019-1015-7","article-title":"Linear scleroderma \u201cen coup de sabre\u201d with extensive brain involvement-Clinicopathologic correlations and response to anti-Interleukin-6 therapy","volume":"14","author":"Magro","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2018.05.001","article-title":"Scleroderma \u201cen coup de sabre\u201d With Epilepsy and Uveitis Successfully Treated With Tocilizumab","volume":"16","author":"Osminina","year":"2020","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"65","DOI":"10.5114\/pdia.2014.40978","article-title":"Antiphospholipid antibodies in localized scleroderma: the potential role of screening tests for the detection of antiphospholipid syndrome","volume":"31","author":"Lis-\u015awi\u0119ty","year":"2014","journal-title":"Postepy Dermatol Alergol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.8.771","article-title":"Antiphospholipid antibody in localised scleroderma","volume":"62","author":"Sato","year":"2003","journal-title":"Ann Rheumatic Diseases"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2007.12.006","article-title":"Vascular disease in scleroderma: angiogenesis and vascular repair","volume":"34","author":"Mulligan-Kehoe","year":"2008","journal-title":"Rheum Dis Clin North Am"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1764835\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T07:37:04Z","timestamp":1770795424000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1764835\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2026.1764835"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1764835","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"article-number":"1764835"}}